Transition Industries and Mexico’s CFEnergía Sign Natural Gas Supply Contract Enabling Construction of Pacifico Mexinol, the World’s Largest Ultra-Low Carbon Methanol Plant
16.2.2026 14:00:00 CET | Business Wire | Press Release
Transition Industries LLC, a developer of world-scale, net-zero carbon emissions methanol and hydrogen projects, and CFEnergía, a subsidiary of Mexico’s Federal Electricity Commission (CFE), announced the signing of a long-term firm natural gas supply contract for the Pacifico Mexinol (“Mexinol”) project, located near Topolobampo, Sinaloa.
Under this agreement, CFEnergía will supply approximately 160 million cubic feet per day (MMcfd) of natural gas over the long term, ensuring a critical input for Mexinol’s production of ultra-low carbon methanol. The supply will be provided by CFEnergía at market prices and will optimize the use of existing infrastructure. CFEnergía will source the natural gas from the USA. The agreement is subject to customary conditions.
The contract signing with CFEnergía represents the final outstanding commercial milestone, enabling the start of the construction phase, and confirming the timeline for Mexinol’s operational readiness in late 2029 to early 2030.
When it initiates operations, Mexinol, a subsidiary of Transition Industries, is expected to be the largest ultra-low carbon chemicals facility in the world – producing approximately 1.8 million MT of blue methanol and 350,000 MT of green methanol annually. With an investment exceeding USD 3.3 billion, its prime location on the west coast of Mexico meets emerging demand for clean methanol in the Pacific and beyond.
“This contract reinforces Mexinol’s position as a key strategic investment, strengthening the long-term industrial competitiveness of Mexico and the state of Sinaloa. The project further creates bilateral economic development through the creation of jobs in both Mexico and the U.S., and the export and consumption of more than US$4 billion worth of U.S. natural gas. The investment is expected to catalyze the development of derivative industries in Mexico and ensure additional domestic consumption of methanol,” said Rommel Gallo, CEO of Transition Industries.
A global-scale industrial asset
The project positions Mexico as a reliable supplier of ultra-low carbon methanol to strategic markets in Asia, including Japan, while also boosting the development of the domestic market and the Mexican chemical industry. Mitsubishi Gas Chemical (MGC), a world-class company based in Tokyo has committed to purchasing approximately 50% of the project's production.
The project's location, near the Port of Topolobampo in the municipality of Ahome, strengthens its export profile, facilitates access to global markets, and improves its logistical competitiveness, while also boosting domestic market development and the integration of the national chemical industry.
Economic and operational impact
Mexinol is committed to the highest environmental and sustainability standards, leveraging technology and innovation to treat and use municipal wastewater instead of seawater and other natural sources of water; supporting the long term socioeconomic development in the local area through generating more than 6,000 jobs in Sinaloa during construction and at least 450 permanent jobs (direct and indirect) in operations; and prioritizing local talent to strengthen the regional industrial ecosystem.
With the gas supply contract secured, Mexinol enters the execution phase, solidifying its position as a key project in the transition to net-zero emissions and establishing itself as a strategic industrial platform for innovation in Mexico.
About Transition Industries LLC
Transition Industries LLC, based in Houston, Texas, is a developer of world-scale, net-zero carbon emissions methanol and hydrogen projects in North America to address climate change and promote environmental and social sustainability. For additional information about Pacifico Mexinol or Transition Industries, email inquiries@transitionind.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260216740732/en/
Contacts
Karin Nunan, Global Head of Corporate Affairs,
knunan@transitionind.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press Release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press Release
Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meury, President and Chief Executive Officer, Incyte. “As the first PD-1 immunotherapy approved in Europe in combination with platinum-based chemotherapy in the first-line setting, Zynyz helps expand the standard-of-care options available to clinicians and underscores our commitment to delivering innovative medicines that can have an impact for patients.” The EC decision follows the January 2026 positive opinion received from the European Medicines Agency’s Committee f
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press Release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press Release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press Release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom